Allogene Therapeutics, Inc. ALLO 深 滬
已收盤 08-21 16:00:00 美东时间
2.09
-0.010
-0.48%
華盛通- 最 高2.15
- 今 開2.12
- 成交量 437.26万股
- 最 低 2.06
- 昨 收 2.10
- 總市值 7.22亿
- 52周最高 4.46
- 市盈率 靜 --
- 換手率 1.27%
- 52周最低 1.04
- 委 比 -47.43%
- 總股本 3.45亿
- 歷史最高 55.00
- 量 比 0.88
- 振 幅 4.29%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Citizens Reiterates Market Outperform on Allogene Therapeutics, Maintains $6 Price Target
Citizens analyst Reni J. Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Market Outperform and maintains $6 price target.
08-17 20:59
Allogene Therapeutics Files Prospectus For $500M Offering
Allogene Therapeutics Files Prospectus For $500M Offering
08-13 05:00
Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $4.640 m...
08-13 04:08
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported progress on its pivotal Phase 2 ALPHA3 trial for cema-cel in high-risk LBCL, with strong execution and site activation ahead of schedule, supporting enrollment. The FDA granted RMAT and Fast Track designations for cema-cel following interim data showing high MRD clearance rates. The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases is also advancing with brisk enrollment. The company ended Q2 2026 with $4...
08-12 20:05
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast T...
07-29 20:32
Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and...
07-13 20:08
Sana Biotechnology To Present Data From Allogeneic Primary Islet Cell Therapy At European Association For The Study Of Diabetes
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell th...
07-01 21:05
Allogene Launches ATM Offering to Bolster Capital Flexibility
Allogene Therapeutics ( ($ALLO) ) has issued an update. At its June 18, 2026 an...
06-23 04:54
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics reported positive interim data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101, a TCR-T therapy for preventing relapse in patients with hematologic malignancies after allo-HCT. Of 14 patients who received TSC-101, 11 achieved complete donor chimerism within three weeks, and two additional patients showed improving chimerism. The therapy was well-tolerated, with safety consistent with post-HCT adverse events. The company ...
06-22 11:00
